GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 195 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $38,540,000 | +506.7% | 565,940 | +184.7% | 0.01% | +400.0% |
| Q2 2022 | $6,352,000 | +13.3% | 198,772 | +22.9% | 0.00% | +100.0% |
| Q1 2022 | $5,604,000 | -61.9% | 161,755 | -67.8% | 0.00% | – |
| Q4 2021 | $14,706,000 | +57.5% | 502,384 | +37.1% | 0.00% | -100.0% |
| Q3 2021 | $9,335,000 | -9.9% | 366,385 | +23.9% | 0.00% | 0.0% |
| Q2 2021 | $10,355,000 | -39.2% | 295,704 | -29.2% | 0.00% | -66.7% |
| Q1 2021 | $17,026,000 | -60.7% | 417,828 | -58.2% | 0.00% | -25.0% |
| Q4 2020 | $43,314,000 | +61.4% | 1,000,138 | +105.4% | 0.00% | -20.0% |
| Q3 2020 | $26,844,000 | -8.2% | 486,820 | +5.1% | 0.01% | -37.5% |
| Q2 2020 | $29,253,000 | -0.9% | 463,381 | -19.8% | 0.01% | -20.0% |
| Q1 2020 | $29,507,000 | -51.0% | 577,548 | -23.8% | 0.01% | -44.4% |
| Q4 2019 | $60,256,000 | +90.3% | 758,037 | +16.2% | 0.02% | +63.6% |
| Q3 2019 | $31,656,000 | -72.6% | 652,444 | -70.3% | 0.01% | -21.4% |
| Q2 2019 | $115,732,000 | +170.2% | 2,200,208 | +171.9% | 0.01% | -22.2% |
| Q1 2019 | $42,831,000 | +46.3% | 809,200 | +13.5% | 0.02% | +63.6% |
| Q4 2018 | $29,267,000 | +9.2% | 712,968 | +1.1% | 0.01% | +22.2% |
| Q3 2018 | $26,806,000 | -65.6% | 705,424 | -59.1% | 0.01% | -67.9% |
| Q2 2018 | $77,916,000 | +174.7% | 1,723,809 | +193.5% | 0.03% | +154.5% |
| Q1 2018 | $28,366,000 | -18.4% | 587,300 | -33.5% | 0.01% | -15.4% |
| Q4 2017 | $34,758,000 | +445.3% | 883,324 | +330.3% | 0.01% | +550.0% |
| Q3 2017 | $6,374,000 | -20.5% | 205,300 | -29.9% | 0.00% | -33.3% |
| Q2 2017 | $8,013,000 | -69.6% | 293,000 | -59.1% | 0.00% | -78.6% |
| Q1 2017 | $26,397,000 | +2553.0% | 716,330 | +941.2% | 0.01% | – |
| Q4 2016 | $995,000 | -69.6% | 68,800 | -51.5% | 0.00% | -100.0% |
| Q3 2016 | $3,273,000 | +38.5% | 142,000 | -0.3% | 0.00% | 0.0% |
| Q2 2016 | $2,363,000 | +798.5% | 142,395 | +757.8% | 0.00% | – |
| Q1 2016 | $263,000 | -42.8% | 16,600 | +52.1% | 0.00% | – |
| Q3 2015 | $460,000 | – | 10,912 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |